Tmunity
ClosedNext-generation T-cell therapies for cancer.
Philadelphia, United States · Founded 2015 · $185.0M raised
- Headquarters
- Philadelphia, Pennsylvania
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- tmunity.com
- Total Funding
- $185.0M
- Last Round
- $75.0M Venture RoundDec 2022
- Rounds
- 4
About
Tmunity Therapeutics developed next-generation engineered T-cell therapies (CAR-T and TCR-T) for solid tumors and hematologic malignancies in oncology. The company collaborated with biopharma partners and clinical centers before being acquired by Kite, a Gilead Company.
Summary
Tmunity is a Biotech company based in Philadelphia, United States, founded in 2015. It has raised $185.0M in total across 4 rounds, most recently a $75.0M Venture Round round in Dec 2022. Investors include Parker Institute for Cancer Immunotherapy, Andreessen Horowitz and Gilead Sciences.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2022
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...